Form 4: Reviva Pharmaceuticals CFO Receives Stock Options as Incentive Bonus

Chief Financial Officer of Reviva Pharmaceuticals, Prabhu Narayan, receives fully vested stock options in lieu of a cash bonus for 2023 performance.

Summary

• Prabhu Narayan, the Chief Financial Officer of Reviva Pharmaceuticals Holdings, Inc., was granted stock options on September 15, 2024.
• These options are fully vested and represent payment of his incentive bonus earned for 2023.
• The option allows Narayan to purchase 96,519 shares of Reviva Pharmaceuticals common stock at an exercise price of $1.20 per share.
• The options expire on September 14, 2034.
• The grant was made by the Issuer's compensation committee in accordance with the terms of the Issuer's 2020 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The document indicates a standard compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive as it reflects a reward for past performance.

Positives

• The granting of stock options aligns the CFO's interests with those of the shareholders.
• The options are fully vested, providing immediate value to the CFO.
• The incentive bonus structure rewards performance and encourages future contributions.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Management Comments

• The Compensation Committee determined the amount of incentive bonus earned by Mr. Prabhu for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment.

Industry Context

Granting stock options to executives is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders. This is especially true for smaller cap companies where cash may be limited.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The specific number of options and exercise price are typically determined based on individual performance, company performance, and market conditions.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
• Employees may see this as a positive sign of recognizing and rewarding contributions.

Key Dates